Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of DNV3 + toripalimab + chemotherapy in unresectable locally advanced or metastatic melanoma after checkpoint inhibitor failure
CTR20243964Phase 2Active
- Sponsor
- Simaide Biopharma
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DNV3, toripalimab in melanoma, sponsored by Simaide Biopharma. Started Nov 2024; status: active.
02
Drugs
DNV3toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20243964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243964.